JP2015506704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506704A5 JP2015506704A5 JP2014555799A JP2014555799A JP2015506704A5 JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5 JP 2014555799 A JP2014555799 A JP 2014555799A JP 2014555799 A JP2014555799 A JP 2014555799A JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant adenovirus
- nucleic acid
- adenovirus
- heterologous nucleic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594005P | 2012-02-02 | 2012-02-02 | |
| US61/594,005 | 2012-02-02 | ||
| PCT/US2013/024506 WO2013116778A2 (en) | 2012-02-02 | 2013-02-01 | Immunogenic adenovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Division JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506704A JP2015506704A (ja) | 2015-03-05 |
| JP2015506704A5 true JP2015506704A5 (enExample) | 2016-03-17 |
| JP6325459B2 JP6325459B2 (ja) | 2018-05-16 |
Family
ID=47714593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555799A Active JP6325459B2 (ja) | 2012-02-02 | 2013-02-01 | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11155599B2 (enExample) |
| EP (1) | EP2809788B1 (enExample) |
| JP (2) | JP6325459B2 (enExample) |
| KR (1) | KR102100092B1 (enExample) |
| CN (2) | CN104271748B9 (enExample) |
| AU (1) | AU2013214776B2 (enExample) |
| BR (1) | BR112014019049A2 (enExample) |
| CA (1) | CA2863523A1 (enExample) |
| DK (1) | DK2809788T3 (enExample) |
| ES (1) | ES2759785T3 (enExample) |
| NZ (1) | NZ628213A (enExample) |
| SG (3) | SG10201606356YA (enExample) |
| WO (1) | WO2013116778A2 (enExample) |
| ZA (1) | ZA201405755B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| CN114317461A (zh) * | 2013-11-22 | 2022-04-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| CN104328140B (zh) * | 2014-10-08 | 2018-06-05 | 兰州大学 | 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒 |
| US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
| AU2016205215B2 (en) | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| CN104762269A (zh) * | 2015-03-18 | 2015-07-08 | 红土生物技术有限公司 | 一种增强肿瘤抗原免疫原性的新策略及其在肺癌免疫治疗中的应用 |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| US11351237B2 (en) | 2015-12-22 | 2022-06-07 | Thomas Jefferson University | CMV-based intra-tumoral cancer therapies |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| RS64059B1 (sr) * | 2016-03-31 | 2023-04-28 | The European Molecular Biology Laboratory | Protein adenoviralnog omotača izveden iz vehikuluma za isporuku |
| US11090344B2 (en) | 2016-05-27 | 2021-08-17 | Dnatrix, Inc. | Adenovirus and immunomodulator combination therapy |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| CA3052090A1 (en) * | 2017-01-30 | 2018-08-02 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| WO2019102268A1 (en) | 2017-11-22 | 2019-05-31 | Mesoblast International Sarl | Cellular compositions and methods of treatment i |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2019237371A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 定点插入 ct1.1 基因的 cho 细胞株的构建方法及其用途 |
| CN109081873B (zh) * | 2018-08-10 | 2022-04-22 | 固安鼎泰海规生物科技有限公司 | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020259189A1 (zh) * | 2019-06-27 | 2020-12-30 | 北京太东生物科技有限公司 | Sox11作为精神分裂症诊断标记物的应用 |
| KR20220038485A (ko) | 2019-08-05 | 2022-03-28 | 메조블라스트 인터내셔널 에스에이알엘 | 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법 |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021194183A1 (ko) * | 2020-03-25 | 2021-09-30 | ㈜큐리진 | 면역 회피성 항종양 아데노바이러스 |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN111850041A (zh) * | 2020-07-30 | 2020-10-30 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法 |
| CN115996735A (zh) | 2020-08-10 | 2023-04-21 | 迈索布拉斯特国际有限公司 | 细胞组合物和治疗方法 |
| JP2025536260A (ja) | 2022-10-11 | 2025-11-05 | イェール ユニバーシティー | 細胞透過性抗体の組成物および使用方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| FI972225L (fi) | 1994-11-28 | 1997-07-16 | Genetic Therapy Inc | Vektorit kudosspesifistä replikaatiota varten |
| WO1996033280A1 (en) | 1995-04-17 | 1996-10-24 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| JP2002514075A (ja) | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| WO2000029599A1 (en) | 1998-11-18 | 2000-05-25 | Canji, Inc. | Viral vectors with late transgene expression |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| EP1180932B1 (en) * | 1999-05-12 | 2012-01-11 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| EP1223947A4 (en) | 1999-10-15 | 2004-12-08 | Canji Inc | TARGETED VECTORS |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| MXPA05014155A (es) * | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| US20070134202A1 (en) | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| CN101607985B (zh) | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2407177A1 (en) * | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| US9314516B2 (en) * | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| KR20160054456A (ko) | 2013-06-18 | 2016-05-16 | 디엔에이트릭스, 인코포레이티드 | 종양용해성 아데노바이러스를 사용한 뇌암의 치료 |
-
2013
- 2013-02-01 WO PCT/US2013/024506 patent/WO2013116778A2/en not_active Ceased
- 2013-02-01 US US14/375,842 patent/US11155599B2/en active Active
- 2013-02-01 SG SG10201606356YA patent/SG10201606356YA/en unknown
- 2013-02-01 KR KR1020147024570A patent/KR102100092B1/ko not_active Expired - Fee Related
- 2013-02-01 CA CA2863523A patent/CA2863523A1/en not_active Abandoned
- 2013-02-01 SG SG10201913795TA patent/SG10201913795TA/en unknown
- 2013-02-01 AU AU2013214776A patent/AU2013214776B2/en not_active Ceased
- 2013-02-01 CN CN201380017639.4A patent/CN104271748B9/zh not_active Expired - Fee Related
- 2013-02-01 BR BR112014019049A patent/BR112014019049A2/pt not_active Application Discontinuation
- 2013-02-01 SG SG11201404495RA patent/SG11201404495RA/en unknown
- 2013-02-01 ES ES13704334T patent/ES2759785T3/es active Active
- 2013-02-01 NZ NZ628213A patent/NZ628213A/en not_active IP Right Cessation
- 2013-02-01 DK DK13704334T patent/DK2809788T3/da active
- 2013-02-01 JP JP2014555799A patent/JP6325459B2/ja active Active
- 2013-02-01 EP EP13704334.5A patent/EP2809788B1/en active Active
- 2013-02-01 CN CN201910116066.XA patent/CN110042086A/zh active Pending
-
2014
- 2014-08-05 ZA ZA2014/05755A patent/ZA201405755B/en unknown
-
2018
- 2018-04-12 JP JP2018076878A patent/JP2018138033A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519847A5 (enExample) | ||
| ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| Vici et al. | Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies | |
| Anderson et al. | Plasmid DNA and viral vector-based vaccines for the treatment of cancer | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| Larocca et al. | Viral vector–based therapeutic cancer vaccines | |
| Gil et al. | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells | |
| JP2016540505A5 (enExample) | ||
| JP2023123609A (ja) | 個別化ワクチン | |
| Kim et al. | Poxviral vectors for cancer immunotherapy | |
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| JP2017501695A5 (enExample) | ||
| CN106029889A (zh) | 表达免疫细胞刺激受体激动剂的腺病毒 | |
| Kim et al. | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures | |
| Goyvaerts et al. | The journey of in vivo virus engineered dendritic cells from bench to bedside: a bumpy road | |
| Lundstrom | Alphaviruses in cancer therapy | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| Osada et al. | Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| JP2020507332A5 (enExample) | ||
| White et al. | Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer | |
| Liljenfeldt et al. | A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells | |
| Olsen et al. | Neuro-Oncology Advances |